Efficacy and safety study of the antihistamine V00114CP 2.5 mg in the treatment of seasonal allergic rhinitis. Randomised, double-blind, three arm parellel group study including placebo and active control
Efficacy and safety study of the antihistamine V00114CP 2.5 mg in the treatment of seasonal allergic rhinitis. Randomised, double-blind, three arm parellel group study including placebo and active control
Efficacy and safety study of the antihistamine V00114CP 2.5 mg in the treatment of seasonal allergic rhinitis. Randomised, double-blind, three arm parellel group study including placebo and active control
Status
Status :
Early termination
Type of study
Phase III
Min. Age
12
Years old
Max. Age
65
Years old
Gender
All
Therapeutic area :
Allergy
Disease :
Allergic rhinitis
Study medication :
L-mequitazine (Xyzall®)
Phase :
Phase III
Start Date :
2008
End date :
19 May 2009
Study ID :
V00114 CP 305 2A
EudraCT/CTIS number :
2008-008734-36
Send by email